Figure 1.
Dual CTLA-4 and PD-L1 blockade inhibits CT26 colon cancer growth. A, growth curves of orthotopically implanted CT26 tumors in mice that received IgG control, anti-CTLA-4, anti-PD-L1 antibodies or a combination of both (anti-CTLA-4 and anti-PD-L1), as determined by MR measurements. B, mean tumor volumes at day 14 p.i. displayed as bar chart. C, representative T2-weighted MR images (first and second column) and images of excised colon tumors at day 14 p.i. (third column) confirm the smallest tumor sizes upon dual immune checkpoint blockade. Percentages of mice with liver metastases (fourth column) show inhibitory effects of immune checkpoint blockade on metastases. Data are presented as mean ± standard deviation. *P < .05, **P < .01, ***P < .001. Scale bar: 1 cm.